• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种研究性喹诺酮、甘氨环素、糖肽、链阳菌素和恶唑烷酮单独及联合对耐万古霉素屎肠球菌的体外活性。

In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.

作者信息

Mercier R C, Penzak S R, Rybak M J

机构信息

Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center, College of Pharmacy and Allied Health Professions, Wayne State University, Michigan 48201, USA.

出版信息

Antimicrob Agents Chemother. 1997 Nov;41(11):2573-5. doi: 10.1128/AAC.41.11.2573.

DOI:10.1128/AAC.41.11.2573
PMID:9371372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC164167/
Abstract

We evaluated the in vitro activities of clinafloxacin, CL331,002, LY333328, quinupristin dalfopristin, and eperezolid (formerly known as U-100,592) against four strains of enterococci. All regimens tested resulted in the growth inhibition of each isolate. Against the three clinafloxacin-susceptible strains, clinafloxacin tested alone was the most active treatment, decreasing the bacterial inoculum by more than 3 log10 CFU/ml after 24 h in time-kill curve studies.

摘要

我们评估了克林沙星、CL331,002、LY333328、奎奴普丁-达福普汀和依哌唑胺（原名U-100,592）对四种肠球菌菌株的体外活性。所有测试方案均导致每种分离株的生长受到抑制。在对三种对克林沙星敏感的菌株进行的时间-杀菌曲线研究中，单独使用克林沙星是最有效的治疗方法，24小时后可使细菌接种量减少超过3个对数10 CFU/ml。

相似文献

1
In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.一种研究性喹诺酮、甘氨环素、糖肽、链阳菌素和恶唑烷酮单独及联合对耐万古霉素屎肠球菌的体外活性。
Antimicrob Agents Chemother. 1997 Nov;41(11):2573-5. doi: 10.1128/AAC.41.11.2573.
2
The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.克林沙星与其他抗菌药物对万古霉素敏感和耐药肠球菌的体外比较活性。
Chemotherapy. 1996 Jul-Aug;42(4):235-9. doi: 10.1159/000239449.
3
Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.在多剂量体外药效学模型中，研究性糖肽类药物LY333328与每日一次庆大霉素联合使用对耐万古霉素屎肠球菌的协同作用。
Antimicrob Agents Chemother. 1999 Mar;43(3):592-7. doi: 10.1128/AAC.43.3.592.
4
[Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].[耐万古霉素肠球菌：奎奴普丁/达福普汀（RP 59500）的体外活性]
Enferm Infecc Microbiol Clin. 1999 Aug-Sep;17(7):335-9.
5
In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.单独及联合使用奎奴普丁/达福普汀对肠球菌属耐药菌株和金黄色葡萄球菌的体外杀菌活性
J Antimicrob Chemother. 1997 May;39 Suppl A:33-9. doi: 10.1093/jac/39.suppl_1.33.
6
Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.红霉素耐药性、接种物生长阶段及孵育时间对RP 59500（奎奴普丁-达福普汀）针对耐万古霉素屎肠球菌杀菌活性评估的影响
Antimicrob Agents Chemother. 1997 Dec;41(12):2749-53. doi: 10.1128/AAC.41.12.2749.
7
Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.奎奴普丁/达福普汀对万古霉素和庆大霉素耐药的粪肠球菌的杀菌和抑菌活性。
J Antimicrob Chemother. 1997 May;39 Suppl A:23-8. doi: 10.1093/jac/39.suppl_1.23.
8
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.半合成糖肽类药物LY333328对万古霉素敏感和耐药的屎肠球菌菌株的时间杀菌曲线。
Antimicrob Agents Chemother. 1997 Jun;41(6):1407-8. doi: 10.1128/AAC.41.6.1407.
9
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.新型糖肽类药物LY333328的药效学评价及其对金黄色葡萄球菌和粪肠球菌的体外活性
Antimicrob Agents Chemother. 1997 Jun;41(6):1307-12. doi: 10.1128/AAC.41.6.1307.
10
Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.克林沙星对耐多药屎肠球菌的活性。
Antimicrob Agents Chemother. 1994 Jul;38(7):1668-70. doi: 10.1128/AAC.38.7.1668.

引用本文的文献

1
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.采用时间杀菌法评估奥利万星与其他抗菌药物联合对金黄色葡萄球菌的协同作用。
Antimicrob Agents Chemother. 2008 Oct;52(10):3820-2. doi: 10.1128/AAC.00361-08. Epub 2008 Jul 21.
2
In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.在体外药效学模型中，单独及与多种抗菌药物联合使用时，奎奴普丁-达福普汀和头孢吡肟对耐多药葡萄球菌和肠球菌的体外活性。
Antimicrob Agents Chemother. 2002 Aug;46(8):2606-12. doi: 10.1128/AAC.46.8.2606-2612.2002.
3
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.在体外药效学模型中，将研究性糖肽奥利万星（LY333328）与万古霉素针对耐多药肺炎链球菌的活性进行比较。
Antimicrob Agents Chemother. 2001 Mar;45(3):706-9. doi: 10.1128/AAC.45.3.706-709.2001.
4
Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.耐万古霉素肠球菌：感染性心内膜炎的治疗
Curr Infect Dis Rep. 1999 Jun;1(2):148-152. doi: 10.1007/s11908-996-0022-8.
5
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.利奈唑胺（PNU-100766）与苯唑西林-双氯西林治疗复杂性皮肤及软组织感染的随机对照研究
Antimicrob Agents Chemother. 2000 Dec;44(12):3408-13. doi: 10.1128/AAC.44.12.3408-3413.2000.
6
Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.LY333328与庆大霉素联合应用于体外及兔实验性心内膜炎中对万古霉素敏感或耐药粪肠球菌的活性研究。
Antimicrob Agents Chemother. 2000 Nov;44(11):3017-21. doi: 10.1128/AAC.44.11.3017-3021.2000.
7
Oxazolidinones: a review.恶唑烷酮类：综述
Drugs. 2000 Jan;59(1):7-16. doi: 10.2165/00003495-200059010-00002.
8
Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.恶唑烷酮类药物利奈唑胺和依哌唑胺在粪肠球菌或耐万古霉素屎肠球菌所致实验性腹腔内脓肿中的活性。
Antimicrob Agents Chemother. 1999 Dec;43(12):2873-6. doi: 10.1128/AAC.43.12.2873.
9
Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.耐万古霉素屎肠球菌对奎奴普丁-达福普汀与其他抗菌药物联合使用的协同性测试。
Antimicrob Agents Chemother. 1999 Nov;43(11):2776-9. doi: 10.1128/AAC.43.11.2776.
10
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.粪肠球菌临床分离株中ParC和GyrA蛋白改变与对九种不同氟喹诺酮类药物耐药性的关联
Antimicrob Agents Chemother. 1999 Oct;43(10):2513-6. doi: 10.1128/AAC.43.10.2513.

本文引用的文献

1
Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots.新型糖肽类药物LY191145与万古霉素对金黄色葡萄球菌及葡萄球菌感染的纤维蛋白凝块的体外活性比较
Antimicrob Agents Chemother. 1995 Dec;39(12):2832-4. doi: 10.1128/AAC.39.12.2832.
2
Initial clinical experience with clinafloxacin in the treatment of serious infections.克林沙星治疗严重感染的初步临床经验。
Drugs. 1995;49 Suppl 2:488-91. doi: 10.2165/00003495-199500492-00145.
3
The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci.vanB基因赋予肠球菌对万古霉素不同水平的自身可转移性耐药性。
J Infect Dis. 1993 May;167(5):1220-3. doi: 10.1093/infdis/167.5.1220.
4
An overview of nosocomial infections, including the role of the microbiology laboratory.医院感染概述，包括微生物实验室的作用。
Clin Microbiol Rev. 1993 Oct;6(4):428-42. doi: 10.1128/CMR.6.4.428.
5
Genetics and mechanisms of glycopeptide resistance in enterococci.肠球菌中糖肽类耐药的遗传学及机制
Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71. doi: 10.1128/AAC.37.8.1563.
6
Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.克林沙星对耐多药屎肠球菌的活性。
Antimicrob Agents Chemother. 1994 Jul;38(7):1668-70. doi: 10.1128/AAC.38.7.1668.
7
Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium.不同β-内酰胺类-糖肽类-庆大霉素联合用药方案对由一株对β-内酰胺类高度耐药且对糖肽类高度耐药的粪肠球菌分离株所致实验性心内膜炎的比较
J Infect Dis. 1995 Jan;171(1):106-12. doi: 10.1093/infdis/171.1.106.
8
In-vitro activity of two glycylcyclines against enterococci resistant to other agents.两种甘氨酰环素对耐其他药物的肠球菌的体外活性。
J Antimicrob Chemother. 1995 Jun;35(6):877-81. doi: 10.1093/jac/35.6.877.
9
Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.新型氟化4-喹诺酮衍生物PD 127,391的体外活性比较
Antimicrob Agents Chemother. 1988 Aug;32(8):1278-81. doi: 10.1128/AAC.32.8.1278.
10
Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital.从一所大学医院的患者中分离出的多重高水平氨基糖苷类耐药肠球菌。
J Clin Microbiol. 1988 Jul;26(7):1287-91. doi: 10.1128/jcm.26.7.1287-1291.1988.